O steoporosis is the most common bone disease in humans, and it has caused major public health problems. Though osteoporosis affects all ages, its prevalence will increase as the population ages worldwide. In recent surveys of the Korean population, the prevalence of osteoporosis was 32.6% in women aged 50 years and above. Osteoporosis can be prevented, diagnosed easily, and treated before any fracture occurs. The active involvement of medical personnel and patients is needed. The prevention and management of osteoporosis are similar to other lifestyle-related diseases. Adequate intake of calcium and vitamin D, regular weight-bearing exercise, fall prevention, and avoidance of tobacco use and excessive alcohol intake are recommended for the general population. Bone mineral density testing and drug treatment must be considered to manage the risk factors of high risk groups. In this study, we review Korean and international research trends, and attempt to present an evidence-based strategy for the management of osteoporosis.
· Women age 65 and older and men age 70 and older, regardless of clinical risk factors · Younger postmenopausal women and men age 50-70 about whom you have concern based on their clinical risk factor profile · Women in the menopausal transition if there is a specific risk factor associated with increased fracture risk such as low body weight, prior low-trauma fracture, or high risk medication. · Adults who have a fracture after age 50 · Adults with a condition (e.g., rheumatoid arthritis) or taking a medication (e.g., glucocorticoids, ≥5 mg/day for ≥3 months) associated with low bone mass or bone loss · Anyone being considered for pharmacologic therapy for osteoporosis · Anyone being treated for osteoporosis, to monitor treatment effect · Anyone not receiving therapy in whom evidence of bone loss would lead to treatment · Postmenopausal women discontinuing estrogen should be considered for bone density testing. · Individuals with vertebral abnormalities · Individuals with primary hyperparathyroidism fractures. · Advise avoidance of tobacco smoking and excessive alcohol intake. · In women age 65 and older and men age 70 and older, recommend BMD testing. · In postmenopausal women and men age 50-70, recommend BMD testing when you have concern based on their risk factor profile. After disease · Recommend BMD testing to those who have suffered a fracture, to determine degree of disease severity.
· Initiate treatment in those with hip or vertebral (clinical or morphometric) fractures. · Initiate therapy in those with BMD T-scores <-2.5 at the femoral neck, total hip, or spine by DXA, after appropriate evaluation. · Initiate treatment in postmenopausal women and in men age 50 and older with low bone mass (T-score -1 to -2.5, osteopenia) at the femoral neck, total hip, or spine and 10-year hip fracture probability ≥3% or a 10-year all major osteoporosis-related fracture probability of ≥20% based on the US-adapted WHO absolute fracture risk model. · Current FDA-approved pharmacologic options for osteoporosis prevention and/or treatment are bisphosphonates (alendronate, ibandronate, risedronate, and zoledronate), calcitonin, estrogens and/or hormone therapy, raloxifene and parathyroid hormone (1-34). Monitoring · BMD testing performed in DXA centers using accepted quality assurance measures is appropriate for monitoring bone loss (recommendation every 2 years). For patients on pharmacotherapy, it is typically performed two years after initiating therapy and at 2-year intervals thereafter. 핵심용어: 골다공증;위험요인;과학적근거;예방
